Zymeworks (ZYME) has released an update.
Zymeworks Inc., a clinical-stage biotech company, reported a strong financial position with $456.3 million in cash resources and a cash runway extending into the second half of 2027. The company announced the initiation of a rolling FDA filing for its cancer drug zanidatamab and a Phase 3 trial, with several regulatory submissions planned through 2024. Zymeworks also highlighted their robust research pipeline with multiple abstracts accepted for a premier cancer research conference.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
